Symptoms and Needs of Patients with Advanced Lung Cancer: Early Prevalence Assessment.


Journal

Oncology research and treatment
ISSN: 2296-5262
Titre abrégé: Oncol Res Treat
Pays: Switzerland
ID NLM: 101627692

Informations de publication

Date de publication:
2019
Historique:
received: 27 02 2019
accepted: 14 08 2019
pubmed: 22 10 2019
medline: 14 4 2020
entrez: 22 10 2019
Statut: ppublish

Résumé

Little is known on symptom burden, psychosocial needs, and perception of prognosis in advanced lung cancer patients at the time of diagnosis, although early assessment is strongly recommended within the setting of daily routine care. Twelve study sites cross-sectionally assessed symptoms and psychosocial needs of patients suffering from newly diagnosed incurable lung cancer. Assessment comprised NCCN distress thermometer, FACT-L, SEIQoL-Q, PHQ-4, and shortened and modified SCNS-SF-34 questionnaires. Additional prognostic information from both patients and physicians were collected. A total of 208 patients were evaluated. Mean age was 63.6 years, 58% were male, 84% suffered from stage IV lung cancer, and 71% had an ECOG performance status of 0-1. Mean distress level was 5.4 (SD 2.5), FACT-L total score was 86 (21.5), and TOI 50.5 (14.9). PHQ-4 was 4.6 (3.3), and shortened and modified SCNS-SF-34 showed 9 (8.7) unmet needs per patient. According to their physicians' perspective, 98.1% of patients were reflecting on and 85.2% were accepting incurability, while 26.5% of patients considered the treatment to be of curative intent. Our findings emphasize substantial domains of symptom burden seen in newly diagnosed, incurable lung cancer patients. Oncologists should be aware of these features and address prognostic issues early in the disease trajectory to facilitate opportunities to improve coping, advance care planning, and appropriate integration of palliative care, thus improving quality of life.

Sections du résumé

BACKGROUND BACKGROUND
Little is known on symptom burden, psychosocial needs, and perception of prognosis in advanced lung cancer patients at the time of diagnosis, although early assessment is strongly recommended within the setting of daily routine care.
METHODS METHODS
Twelve study sites cross-sectionally assessed symptoms and psychosocial needs of patients suffering from newly diagnosed incurable lung cancer. Assessment comprised NCCN distress thermometer, FACT-L, SEIQoL-Q, PHQ-4, and shortened and modified SCNS-SF-34 questionnaires. Additional prognostic information from both patients and physicians were collected.
RESULTS RESULTS
A total of 208 patients were evaluated. Mean age was 63.6 years, 58% were male, 84% suffered from stage IV lung cancer, and 71% had an ECOG performance status of 0-1. Mean distress level was 5.4 (SD 2.5), FACT-L total score was 86 (21.5), and TOI 50.5 (14.9). PHQ-4 was 4.6 (3.3), and shortened and modified SCNS-SF-34 showed 9 (8.7) unmet needs per patient. According to their physicians' perspective, 98.1% of patients were reflecting on and 85.2% were accepting incurability, while 26.5% of patients considered the treatment to be of curative intent.
CONCLUSION CONCLUSIONS
Our findings emphasize substantial domains of symptom burden seen in newly diagnosed, incurable lung cancer patients. Oncologists should be aware of these features and address prognostic issues early in the disease trajectory to facilitate opportunities to improve coping, advance care planning, and appropriate integration of palliative care, thus improving quality of life.

Identifiants

pubmed: 31634889
pii: 000502751
doi: 10.1159/000502751
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

650-659

Informations de copyright

© 2019 S. Karger AG, Basel.

Auteurs

Jonas Kuon (J)

Department of Thoracic Oncology, Translational Lung Research Center Heidelberg TLRC-H, Thoraxklinik at Heidelberg University Hospital, Member of the German Center for Lung Research DZL, Heidelberg, Germany, jonas.kuon@med.uni-heidelberg.de.

Jeannette Vogt (J)

University Cancer Center Leipzig, Leipzig, Germany.

Anja Mehnert (A)

Department of Medical Psychology and Medical Sociology, University Hospital Leipzig, Leipzig, Germany.

Bernd Alt-Epping (B)

Department of Palliative Medicine, University Medical Center Göttingen, Göttingen, Germany.

Birgitt van Oorschot (B)

Interdisciplinary Department of Palliative Medicine, University Hospital Würzburg, Würzburg, Germany.

Jochen Sistermanns (J)

Department of Radiation Oncology, Kliniken Maria Hilf, Mönchengladbach, Germany.

Miriam Ahlborn (M)

Department of Oncology and Hematology, Klinikum Braunschweig, Braunschweig, Germany.

Ulrike Ritterbusch (U)

Westdeutsches Tumorzentrum, University Hospital Essen, Essen, Germany.

Susanne Stevens (S)

Department of Medical Oncology, Kliniken Essen Mitte, Essen, Germany.

Christoph Kahl (C)

Department of Hematology, Oncology and Palliative Care, Klinikum Magdeburg, Magdeburg, Germany.

Anne Ruellan (A)

Department of Hematology and Oncology, Stadtisches Klinikum Karlsruhe, Karlsruhe, Germany.

Kathrin Matthias (K)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

Thomas Kubin (T)

Department of Haematology Oncology and Palliative Care, Klinikum Traunstein, Traunstein, Germany.

Kerstin Stahlhut (K)

Ambulatory of Haematology Oncology and Palliative Care, Immanuel Klinik und Poliklinik Rüdersdorf, Berlin, Germany.

Andrea Heider (A)

Department of Medicine 3, Klinikum Leverkusen, Leverkusen, Germany.

Florian Lordick (F)

University Cancer Center Leipzig, Leipzig, Germany.

Michael Thomas (M)

Department of Thoracic Oncology, Translational Lung Research Center Heidelberg TLRC-H, Thoraxklinik at Heidelberg University Hospital, Member of the German Center for Lung Research DZL, Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH